{"entity":{"id":"opamtistomig","kind":"drug","name":"Opamtistomig","aka":["LBL-024"],"tldr":"Opamtistomig is an experimental bispecific antibody from Nanjing Leads Biolabs, in phase 3 trials for extrapulmonary neuroendocrine carcinoma, small cell lung cancer and non-small cell lung cancer and other cancers.","summary":"Opamtistomig (LBL-024) is a bispecific antibody (2:2 format) from Nanjing Leads Biolabs. A bispecific antibody with two binding sites each for PD-L1 and the co-stimulatory receptor 4-1BB, intended to reverse PD-L1-mediated immune suppression while selectively boosting T-cell activation. Its furthest stage is phase 3, for extrapulmonary neuroendocrine carcinoma, small cell lung cancer, non-small cell lung cancer and biliary tract cancer. ClinicalTrials.gov registers it in 11 studies linked below. Marketing application for monotherapy in previously treated advanced extrapulmonary neuroendocrine carcinoma accepted by China's CDE with priority review (priority review 10 July 2026; acceptance reported 24 August 2026). Single-arm registrational trial; a phase 3 trial NCT07720193 is registered, not yet recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-3","asOf":"2026-11-03","links":[{"label":"Nanjing Leads Biolabs: leadsbiolabs.com","url":"https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js"},{"label":"Nanjing Leads Biolabs: leadsbiolabs.com","url":"https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js"},{"label":"Nanjing Leads Biolabs: biospace.com","url":"https://www.biospace.com/press-releases/priority-review-granted-to-pd-l1-4-1bb-bispecific-antibody-opamtistomig-accelerating-commercialization-and-addressing-unmet-need-in-ep-nec"},{"label":"Nanjing Leads Biolabs: biospectrumasia.com","url":"https://biospectrumasia.com/news/99/28249/leads-biolabs-opamtistomig-nda-accepted-in-china-for-neuroendocrine-carcinoma.html"},{"label":"ClinicalTrials.gov: trials of LBL-024","url":"https://clinicaltrials.gov/search?intr=LBL-024"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["extrapulmonary-nec","nsclc","oesophageal-squamous-cell-carcinoma","melanoma","tnbc","platinum-resistant-ovarian-cancer","colorectal"],"sections":[],"technologies":[],"targets":["pdl1","cd137"],"drugs":[],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05170958","nct06157827","nct06783647","nct07042802","nct07099430","nct07111546","nct07281976","nct07331155","nct07390383","nct07720193","nct07791758"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"LBL-024","modality":"Bispecific antibody (2:2 format)","mechanism":"A bispecific antibody with two binding sites each for PD-L1 and the co-stimulatory receptor 4-1BB, intended to reverse PD-L1-mediated immune suppression while selectively boosting T-cell activation.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/opamtistomig/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}],"trial":[{"id":"nct06783647","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","route":"/trials/nct06783647/"},{"id":"nct07111546","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","route":"/trials/nct07111546/"},{"id":"nct07791758","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma","route":"/trials/nct07791758/"},{"id":"nct06157827","kind":"trial","name":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","route":"/trials/nct06157827/"},{"id":"nct05170958","kind":"trial","name":"A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors","route":"/trials/nct05170958/"},{"id":"nct07331155","kind":"trial","name":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","route":"/trials/nct07331155/"},{"id":"nct07390383","kind":"trial","name":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","route":"/trials/nct07390383/"},{"id":"nct07042802","kind":"trial","name":"A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer","route":"/trials/nct07042802/"},{"id":"nct07720193","kind":"trial","name":"A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC","route":"/trials/nct07720193/"},{"id":"nct07281976","kind":"trial","name":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","route":"/trials/nct07281976/"},{"id":"nct07099430","kind":"trial","name":"A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.","route":"/trials/nct07099430/"}]}}